financetom
Business
financetom
/
Business
/
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata
Mar 5, 2024 1:21 PM

04:04 PM EST, 03/05/2024 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Tuesday it started the phase 2b trial for rezpegaldesleukin to treat patients experiencing severe to very severe alopecia areata.

The Phase 2b study will evaluate rezpegaldesleukin's efficacy and safety in 84 participants with severe alopecia areata over a 36-week period using a randomized, double-blind, placebo-controlled dosage, Nektar said.

Alopecia areata is a disease where the patient's immune system attacks hair follicles, resulting in hair loss.

Rezpegaldesleukin is an agonistic T regulatory cell biologic that reduces inflammation and restores immune balance by expanding functional T regulatory cells and "engaging multiple immunoregulatory pathways," the company said.

Nektar shares fell 2% in recent Tuesday trading.

Price: 0.88, Change: -0.02, Percent Change: -1.97

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gibson Energy Posts Q1 Net Income Drop Despite Higher Revenues
Gibson Energy Posts Q1 Net Income Drop Despite Higher Revenues
Apr 29, 2024
04:29 PM EDT, 04/29/2024 (MT Newswires) -- Gibson Energy ( GBNXF ) after trade Monday reported a first-quarter net income miss, despite higher revenues. The oil infrastructure and marketing company reported net income of C$40 million in the first quarter, a C$48 million or 54% decrease over the first quarter of 2023 and compared to a Capital IQ forecast of...
Old National Bancorp Insider Sold Shares Worth $803,825, According to a Recent SEC Filing
Old National Bancorp Insider Sold Shares Worth $803,825, According to a Recent SEC Filing
Apr 29, 2024
04:27 PM EDT, 04/29/2024 (MT Newswires) -- Brendon B Falconer, CFO, on April 25, 2024, sold 49,375 shares in Old National Bancorp ( ONB ) for $803,825. Following the Form 4 filing with the SEC, Falconer has control over a total of 88,712 shares of the company, with 88,712 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/707179/000112760224013559/xslF345X03/form4.xml ...
BRIEF-Hologic To Acquire Endomagnetics Ltd, A Breast Surgical Guidance Company
BRIEF-Hologic To Acquire Endomagnetics Ltd, A Breast Surgical Guidance Company
Apr 29, 2024
April 29 (Reuters) - Hologic Inc ( HOLX ): * HOLOGIC TO ACQUIRE ENDOMAGNETICS LTD, A BREAST SURGICAL GUIDANCE COMPANY * HOLOGIC INC ( HOLX ) - PROPOSED DEAL FOR FOR APPROXIMATELY $310 MILLION * HOLOGIC ( HOLX )- DEAL EXPECTED TO BE SLIGHTLY DILUTIVE TO HOLOGIC'S NON-GAAP EARNINGS PER SHARE IN FISCAL 2024, BREAK EVEN IN 2025 AND ACCRETIVE...
Lattice Semiconductor Reports Q1 Results, Guides Q2 Revenue Below Estimates
Lattice Semiconductor Reports Q1 Results, Guides Q2 Revenue Below Estimates
Apr 29, 2024
Lattice Semiconductor Corporation ( LSCC ) reported its first-quarter financial results after the bell Monday. Here's a look at the details. The Details: Lattice Semiconductor ( LSCC ) reported quarterly earnings of 29 cents per share which beat the analyst consensus estimate of 28 cents and is a 43.14% decrease from earnings of 51 cents per share from the same...
Copyright 2023-2025 - www.financetom.com All Rights Reserved